New hope for mystery cancers: immunotherapy shows promise

NCT ID NCT03752333

Completed Disease control Sponsor: Imperial College London Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the immunotherapy drug pembrolizumab in 35 adults with cancer of unknown primary (CUP), a cancer that starts in an unknown location. Participants received the drug intravenously, and researchers measured how many saw their tumors shrink or disappear. The goal was to control the disease, not cure it, and the study is now complete.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER OF UNKNOWN PRIMARY SITE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer of unknown primary site carcinoma neoplasm Neoplasms, Unknown Primary

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER OF UNKNOWN PRIMARY SITE

Contacts and locations

Locations

Gastrointestinal Units, The Royal Marsden NHS Foundation Trust (Sutton and Chelsea)

Sutton, Surrey, United Kingdom
Guy's Cancer Centre, Guy's and St Thomas' NHS Foundation Trust

London, United Kingdom
Hammersmith Hospital - Imperial College Healthcare NHS Trust

Hammersmith, London, W12 0HS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.